{
    "title": "115_s1348",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Stopping the Pharmaceutical Industry \nfrom Keeping Drugs Expensive (SPIKE) Act of 2017''.\n\nSEC. 2. DRUG MANUFACTURER PRICE TRANSPARENCY.\n\n    Title XI of the Social Security Act (42 U.S.C. 1301 et seq.) is \namended by inserting after section 1128I the following new section:\n\n``SEC. 1128J. DRUG MANUFACTURER PRICE TRANSPARENCY.\n\n    ``(a) In General.--Effective beginning on January 1, 2018, subject \nto subsection (e), the Secretary shall require a manufacturer of an \napplicable drug to submit to the Secretary the justification described \nin subsection (c) in accordance with the timing described in subsection \n(d).\n    ``(b) Definitions.--In this section:\n            ``(1) Applicable drug.--Subject to paragraph (2), the term \n        `applicable drug' means a drug, as defined in section 201(g) of \n        the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)), \n        that is subject to section 503(b)(1) of such Act (21 U.S.C. \n        353(b)(1)), and that the Secretary determines is described in \n        either of the following subparagraphs:\n                    ``(A) The drug (per dose)--\n                            ``(i) has a wholesale acquisition cost of \n                        at least $10 dollars; and\n                            ``(ii) had an increase in the wholesale \n                        acquisition cost of the drug, with respect to \n                        determinations made--\n                                    ``(I) during 2019, of at least 100 \n                                percent since the date of the enactment \n                                of this section;\n                                    ``(II) during 2020, of at least 100 \n                                percent in the preceding 12 months or \n                                of at least 150 percent in the \n                                preceding 2 years;\n                                    ``(III) during 2021, of at least \n                                100 percent in the preceding 12 months \n                                or of at least 200 percent in the \n                                preceding 3 years;\n                                    ``(IV) during 2022, of at least 100 \n                                percent in the preceding 12 months or \n                                of at least 250 percent in the \n                                preceding 4 years; or\n                                    ``(V) on or after January 1, 2023, \n                                of at least 100 percent in the \n                                preceding 12 months or of at least 300 \n                                percent in the preceding 5 years.\n                    ``(B) The drug (per dose)--\n                            ``(i) is in the top 50th percentile of net \n                        spending under title XVIII or XIX in at least \n                        one of the preceding 5 years; and\n                            ``(ii) had an increase in the wholesale \n                        acquisition cost of the drug, with respect to \n                        determinations made--\n                                    ``(I) during 2019, of at least 15 \n                                percent since the date of the enactment \n                                of this section;\n                                    ``(II) during 2020, of at least 15 \n                                percent in the preceding 12 months or \n                                of at least 20 percent in the preceding \n                                2 years;\n                                    ``(III) during 2021, of at least 15 \n                                percent in the preceding 12 months or \n                                of at least 30 percent in the preceding \n                                3 years;\n                                    ``(IV) during 2022, of at least 15 \n                                percent in the preceding 12 months or \n                                of at least 40 percent in the preceding \n                                4 years; or\n                                    ``(V) on or after January 1, 2023, \n                                of at least 15 percent in the preceding \n                                12 months or of at least 50 percent in \n                                the preceding 5 years.\n            ``(2) Special rule.--For purposes of applying paragraph \n        (1), the Secretary may substitute for each percentage described \n        in subparagraph (A) or (B) of such paragraph (other than the \n        percentile described subparagraph (B)(i) of such paragraph) a \n        percentage within a de minimis range specified by the Secretary \n        below the percentage so described.\n            ``(3) Manufacturer.--The term `manufacturer' has the \n        meaning given that term in section 581(10) of the Federal Food, \n        Drug, and Cosmetic Act (21 U.S.C. 360eee(10)).\n            ``(4) Wholesale acquisition cost.--The term `wholesale \n        acquisition cost' has the meaning given that term in section \n        1847A(c)(6)(B).\n    ``(c) Justification Described.--The justification described in this \nsubsection is all relevant information and supporting documentation \nnecessary to justify the increase in the wholesale acquisition cost of \nthe applicable drug of the manufacturer, which may include the \nfollowing:\n            ``(1) The individual factors that have contributed to the \n        increase in the wholesale acquisition cost.\n            ``(2) An explanation of the role of each factor in \n        contributing to such increase.\n            ``(3) Total expenditures of the manufacturer on--\n                    ``(A) materials and manufacturing for such drug;\n                    ``(B) acquiring patents and licensing for each drug \n                of the manufacturer; and\n                    ``(C) costs to purchase or acquire the drug from \n                another company, if applicable.\n            ``(4) The percentage of total expenditures of the \n        manufacturer on research and development for such drug that was \n        derived from Federal funds.\n            ``(5) The total expenditures of the manufacturer on \n        research and development for such drug.\n            ``(6) The total revenue and net profit generated from the \n        applicable drug for each calendar year since drug approval.\n            ``(7) The total costs associated with marketing and \n        advertising for the applicable drug.\n            ``(8) Additional information specific to the manufacturer \n        of the applicable drug, such as--\n                    ``(A) the total revenue and net profit of the \n                manufacturer for the period of such increase, as \n                determined by the Secretary;\n                    ``(B) metrics used to determine executive \n                compensation;\n                    ``(C) any additional information related to drug \n                pricing decisions of the manufacturer, such as total \n                expenditures on--\n                            ``(i) drug research and development; or\n                            ``(ii) clinical trials on drugs that failed \n                        to receive approval by the Food and Drug \n                        Administration.\n    ``(d) Timing.--\n            ``(1) Notification.--Not later than 60 days after the date \n        on which the Secretary makes the determination that a drug is \n        an applicable drug under subsection (b), the Secretary shall \n        notify the manufacturer of the applicable drug of such \n        determination.\n            ``(2) Submission of justification.--Not later than 180 days \n        after the date on which a manufacturer receives a notification \n        under paragraph (1), the manufacturer shall submit to the \n        Secretary the justification required under subsection (a).\n            ``(3) Posting on internet website.--\n                    ``(A) In general.--Subject to subparagraph (B), not \n                later than 30 days after receiving the justification \n                under paragraph (2), the Secretary shall post on the \n                Internet website of the Centers for Medicare & Medicaid \n                Services the justification, together with a summary of \n                such justification that is written and formatted using \n                language that is easily understandable by beneficiaries \n                under titles XVIII and XIX.\n                    ``(B) Exception.--The Secretary shall establish a \n                process under which a manufacturer of an applicable \n                drug may submit a request to the Secretary that certain \n                proprietary information disclosed as part of \n                justification in subsection (c) be excluded from the \n                posting described in subparagraph (A) if, as determined \n                by the Secretary (in consultation with the Inspector \n                General of the Department of Health and Human \n                Services), the public disclosure of such information \n                would directly lead to increased prices of prescription \n                drugs. If proprietary information is excluded from the \n                posting pursuant to the preceding sentence, to the \n                extent feasible, the summary of the information \n                described in subparagraph (A) shall include a summary \n                of such proprietary information.\n    ``(e) Exception to Requirement for Submission.--The requirement to \nsubmit a justification under subsection (a) shall not apply in the case \nwhere the manufacturer, after receiving the notification under \nsubsection (d)(1) with respect to an applicable drug of the \nmanufacturer, reduces the wholesale acquisition cost of a drug so that \nit no longer meets the definition of an applicable drug under \nsubsection (b) for at least a 6-month period, as determined by the \nSecretary.\n    ``(f) Penalties.--The provisions of subsection (b)(3)(C) of section \n1927 shall apply to a manufacturer that fails to submit the \njustification required under subsection (a) on a timely basis or that \nknowingly provides false information in the same manner as such \nprovisions apply to a manufacturer with an agreement under that \nsection.''."
}